Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| A.M.L. | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
This study aims to learn more about anal cancer risk in men who have sex with men (MSM) who are using Pre-Exposure Prophylaxis (PrEP) to prevent HIV. Specifically, we want to check how common High-Grade Squamous Intraepithelial Lesions (HSIL) are in this group, how well anal swabs can screen for these lesions, and how having HSIL affects their quality of life. We'll also test if DNA methylation testing can give us extra information about the lesions.
The main questions the study aims to answer are:
Participants will:
This study aims to evaluate High-Grade Squamous Intraepithelial Lesions (HSIL) in men who have sex with men (MSM) using Pre-Exposure Prophylaxis (PrEP) for HIV prevention. MSM are at increased risk for developing anal cancer, and HSIL is a known precursor to this type of cancer. The study seeks to assess the prevalence of HSIL, the screening accuracy of anal swabs, and the impact of HSIL on quality of life for MSM using PrEP. Furthermore, the study will explore the use of DNA methylation testing as a potential tool for improving the detection and understanding of HSIL in this high-risk group.
This multicenter clinical trial will involve MSM using PrEP at several study sites to ensure a diverse and representative sample.
The study will focus on prevalence, screening accuracy, and quality of life impacts, and will incorporate DNA methylation testing to explore potential molecular markers for early detection and progression of HSIL.
The primary goal of the study is to improve the early detection of HSIL in MSM using PrEP. By evaluating screening methods and quality of life, this study aims to provide valuable data that could lead to more effective screening strategies and interventions for preventing anal cancer in this population. The use of DNA methylation testing will provide additional insights into the molecular biology of HSIL, potentially informing future screening protocols.
This study addresses a significant gap in current research regarding the prevention and early detection of anal cancer in MSM using PrEP and aims to contribute critical data to improve healthcare outcomes for this high-risk population.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| MSM group | Experimental | The MSM group consists of men who have sex with men (MSM) who are using Pre-Exposure Prophylaxis (PrEP) for HIV prevention. Participants in this group will undergo the following interventions:
|
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Anal smear | Diagnostic Test | The intervention in this study involves the anal smear collection using the FLOQSwab® (COPAN, pouch type 502CS01). The swab is inserted 3-5 cm into the anal canal, reaching the transitional zone, the pressed against the canal wall and withdrawn in a spiral motion over approximately 20 seconds. After collection, the swab is immediately placed into a ThinPrep vial containing 20 ml of PreservCyt® and rinsed vigorously. The procedure is performed by a physician or trained study team member and is designed to be quick, minimally invasive, and comfortable for participants. The FLOQSwab®'s patient-friendly design reduces irritation and false-positive results in comparison to earlier methods. Samples collected in the ThinPrep PreservCyt® solution should be stored at room temperature and transferred to AML within a maximum of six weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Prevalence of anal high-risk HPV infection in MSM-PrEP in Belgium | The primary endpoint aims to determine the prevalence of HR HPV in MSM-PrEP in Belgium. | From screening to study completion for the patient (on average 8 months). |
| Measure | Description | Time Frame |
|---|---|---|
| Prevalence of abnormal anal cytology in MSM using PrEP in Belgium | The secondary endpoint aims to determine the prevalence of abnormal anal cytology in MSM using PrEP in Belgium | From screening to study completion for the patient (on average 8 months). |
| Prevalence of abnormal histology, i.e. LSIL and HSIL in MSM using PrEP in Belgium |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Magali Surmont | Contact | 024776001 | magali.surmont@uzbrussel.be |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| AZ Sint Jan | Active, not recruiting | Bruges | 8000 | Belgium | ||
| CHU Saint-Pierre |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Self-administered questionnaire | Behavioral | It includes questions related to: Socio-demographic characteristics Health-related issues Past HPV vaccination (indication? age at vaccination?) History of condylomata and/or other STIs Drug use, tobacco use, alcohol use Anal symptoms: discomfort, itch, pain, nodules, blood loss/discharge, constipation Sexual behavior Insertive/receptive intercourse, chemsex, number of sex partners (stable, occasional, anonymous), condom use. |
|
| EQ-5D-5L questionnaire | Behavioral | This questionnaire will be used after a negative HRA or during the communication of the results (per telephone) and during the treatment if indicated. This questionnaire assesses the impact of health conditions and treatments on person's quality of life. We will use an adapted version of the EQ-5D-5L. This modified version includes additional questions tailored to assess specific domains highlighted in the A-HRSI. The additional items cover:
|
|
| High Resolution Anoscopy (HRA) | Diagnostic Test | HRA will be conducted using advanced tools, such as the Zeiss Extaro at UZ Brussel. HRA will be conducted at participating centers with expertise in the technique, including UZ Brussel, UZ Gent, UZ Leuven, UZ Antwerpen, CHU St Pierre, AZ Sint-Jan Brugge, and Citadelle Liège. However, all biopsy specimens will be sent to AML Lab for analysis and stored in the biobank (BB190002). In certain centers, HRA is performed using high-resolution scopes. |
|
The third endpoint aims to determine the prevalence of abnormal anal histology in MSM using PrEP in Belgium |
| From screening to study completion for the patient (on average 8 months). |
| Methylation on cytology (screening) samples and histology (HRA) samples | The fourth endpoint aims to investigate methylation profiles according to the cytological or histo-logical results | From screening to study completion for the patient (on average 8 months). |
| Accuracy of anal HPV genotyping, anal cytology and methylation, together or as separate tests in the prediction of hHSIL | The fifth endpoint aims to determinate the specificity and sensitivity of anal HPV genotyping, anal cytology and methylation, together and as separate tests, used as screening tests for hHSIL. | From screening to study completion for the patient (on average 8 months). |
| Can we distinguish different profiles in hHSIL suggesting repression or progression? | profiling hHSIL in terms of methylation and biomarkers such as HPV genotyping, HPV-E4, p16 and Ki67 | From screening to study completion for the patient (on average 8 months). |
| Can ASCL1/ZNF582 methylation test make accuracy of the less invasive anal swab testing better and/or be used to guide treatment decision making? | Receiver operating curve analysis of anal swabs for hHSIL detection with or without methylation testing on anal swab. | From screening to study completion for the patient (on average 8 months). |
| Determine the incidence of HPV related lesions between demographics, lifestyle, HPV vaccination, sexual risk behavior, history of STI and HPV infection, cytology and histology. | Determination of (multiple) correlations between demographics, lifestyle, HPV vaccination, sexual risk behavior, history of STIs versus HPV infection and abnormal cytohistology. | From screening to study completion for the patient (on average 8 months). |
| Impact of anal cancer screening in MSM using PrEP on quality of life | Determination of quality of life using EQ-5D questionnaire (annex 1) at screening and follow-up in MSM using PrEP. | From screening to study completion for the patient (on average 8 months). |
| Recruiting |
| Brussels |
| 1000 |
| Belgium |
|
| Cliniques universitaires Saint-Luc - UCLouvain | Recruiting | Brussels | 1200 | Belgium |
|
| UZ Brussel | Recruiting | Brussels | Belgium |
|
| UZ Gent | Recruiting | Ghent | 9000 | Belgium |
|
| Jessaziekenhuis | Recruiting | Hasselt | Belgium |
|
| UZ Leuven | Active, not recruiting | Leuven | 3000 | Belgium |
| CHU Charleroi - Chimay | Recruiting | Lodelinsart | 6042 | Belgium |
|
| ID | Term |
|---|---|
| D001005 | Anus Neoplasms |
| D000081483 | Squamous Intraepithelial Lesions |
| D002294 | Carcinoma, Squamous Cell |
| D006716 | Homosexuality |
| ID | Term |
|---|---|
| D012004 | Rectal Neoplasms |
| D015179 | Colorectal Neoplasms |
| D007414 | Intestinal Neoplasms |
| D005770 | Gastrointestinal Neoplasms |
| D004067 | Digestive System Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D004066 | Digestive System Diseases |
| D005767 | Gastrointestinal Diseases |
| D007410 | Intestinal Diseases |
| D001004 | Anus Diseases |
| D012002 | Rectal Diseases |
| D065308 | Morphological and Microscopic Findings |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D002277 | Carcinoma |
| D009375 | Neoplasms, Glandular and Epithelial |
| D009370 | Neoplasms by Histologic Type |
| D018307 | Neoplasms, Squamous Cell |
| D019529 | Sexuality |
| D012725 | Sexual Behavior |
| D001519 | Behavior |
Not provided
Not provided